Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure - PubMed (original) (raw)
Clinical Trial
. 2018 Aug 15;122(4):683-688.
doi: 10.1016/j.amjcard.2018.04.062. Epub 2018 May 19.
Affiliations
- PMID: 29961562
- DOI: 10.1016/j.amjcard.2018.04.062
Free article
Clinical Trial
Usefulness of Oral Ferric Citrate in Patients With Iron-Deficiency Anemia and Chronic Kidney Disease With or Without Heart Failure
Peter A McCullough et al. Am J Cardiol. 2018.
Free article
Abstract
Patients with chronic inflammatory conditions including chronic kidney disease (CKD) and heart failure (HF) are undertreated with iron-deficiency anemia (IDA). Progressive inflammation and reduced iron transport associated with CKD and HF may reduce the efficacy of oral iron therapy. Oral ferric citrate improves anemia markers in CKD, but its effects in patients with CKD and concomitant HF have not been described. Patients with CKD not on dialysis and IDA from a phase 2 and 3 trial were treated with ferric citrate (n = 190) or placebo (n = 188); patients with HF were identified from medical histories. Hemoglobin response was defined as a ≥10.0-g/L increase in hemoglobin. Changes in hemoglobin, transferrin saturation, ferritin, and serum phosphate from baseline to week 12 and the incidence of adverse events potentially related to HF were evaluated. HF was reported in 22% (n = 81) of patients. The proportion of patients with hemoglobin response to ferric citrate treatment did not significantly differ in patients with and without HF (43% vs 49%, respectively; p = 0.47); changes from baseline in hemoglobin, iron parameters, and serum phosphate were similar. Adverse events potentially related to HF were noted more frequently in patients with HF (ferric citrate, 23%; placebo, 17%) versus those without HF (ferric citrate, 12%; placebo, 11%). In conclusion, these results indicate a potential role for ferric citrate in the treatment of IDA in patients with CKD not on dialysis and concomitant HF.
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.
Similar articles
- A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.
Block GA, Fishbane S, Rodriguez M, Smits G, Shemesh S, Pergola PE, Wolf M, Chertow GM. Block GA, et al. Am J Kidney Dis. 2015 May;65(5):728-36. doi: 10.1053/j.ajkd.2014.10.014. Epub 2014 Nov 4. Am J Kidney Dis. 2015. PMID: 25468387 Clinical Trial. - Effect of Ferric Citrate versus Ferrous Sulfate on Iron and Phosphate Parameters in Patients with Iron Deficiency and CKD: A Randomized Trial.
Womack R, Berru F, Panwar B, Gutiérrez OM. Womack R, et al. Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1251-1258. doi: 10.2215/CJN.15291219. Epub 2020 Jul 21. Clin J Am Soc Nephrol. 2020. PMID: 32694162 Free PMC article. Clinical Trial. - Safety and Efficacy of Intravenous Ferric Derisomaltose Compared to Iron Sucrose for Iron Deficiency Anemia in Patients with Chronic Kidney Disease With and Without Heart Failure.
Ambrosy AP, von Haehling S, Kalra PR, Court E, Bhandari S, McDonagh T, Cleland JGF. Ambrosy AP, et al. Am J Cardiol. 2021 Aug 1;152:138-145. doi: 10.1016/j.amjcard.2021.04.042. Epub 2021 Jun 20. Am J Cardiol. 2021. PMID: 34162484 Clinical Trial. - Novel Oral Iron Therapies for Iron Deficiency Anemia in Chronic Kidney Disease.
Pergola PE, Fishbane S, Ganz T. Pergola PE, et al. Adv Chronic Kidney Dis. 2019 Jul;26(4):272-291. doi: 10.1053/j.ackd.2019.05.002. Adv Chronic Kidney Dis. 2019. PMID: 31477258 Review. - Ferric Maltol: A New Oral Iron Formulation for the Treatment of Iron Deficiency in Adults.
Khoury A, Pagan KA, Farland MZ. Khoury A, et al. Ann Pharmacother. 2021 Feb;55(2):222-229. doi: 10.1177/1060028020941014. Epub 2020 Jul 7. Ann Pharmacother. 2021. PMID: 32633548 Review.
Cited by
- Long-term safety and efficacy of ferric citrate in phosphate-lowering and iron-repletion effects among patients with on hemodialysis: A multicenter, open-label, Phase IV trial.
Lee CT, Lee CC, Wu MJ, Chiu YW, Leu JG, Wu MS, Peng YS, Wu MS, Tarng DC. Lee CT, et al. PLoS One. 2022 Mar 3;17(3):e0264727. doi: 10.1371/journal.pone.0264727. eCollection 2022. PLoS One. 2022. PMID: 35239732 Free PMC article. - Effect of iron supplementation in patients with heart failure and iron deficiency: A systematic review and meta-analysis.
Yamani N, Ahmed A, Gosain P, Fatima K, Shaikh AT, Qamar H, Shahid I, Arshad MS, Almas T, Figueredo V. Yamani N, et al. Int J Cardiol Heart Vasc. 2021 Sep 14;36:100871. doi: 10.1016/j.ijcha.2021.100871. eCollection 2021 Oct. Int J Cardiol Heart Vasc. 2021. PMID: 34584938 Free PMC article. - Treatment of Iron Deficiency Anemia in CKD and End-Stage Kidney Disease.
Gutiérrez OM. Gutiérrez OM. Kidney Int Rep. 2021 Jun 5;6(9):2261-2269. doi: 10.1016/j.ekir.2021.05.020. eCollection 2021 Sep. Kidney Int Rep. 2021. PMID: 34514189 Free PMC article. Review. - Anemia, Iron Status, and HIV: A Systematic Review of the Evidence.
Abioye AI, Andersen CT, Sudfeld CR, Fawzi WW. Abioye AI, et al. Adv Nutr. 2020 Sep 1;11(5):1334-1363. doi: 10.1093/advances/nmaa037. Adv Nutr. 2020. PMID: 32383731 Free PMC article. - Ferric citrate reduces fibroblast growth factor 23 levels and improves renal and cardiac function in a mouse model of chronic kidney disease.
Francis C, Courbon G, Gerber C, Neuburg S, Wang X, Dussold C, Capella M, Qi L, Isakova T, Mehta R, Martin A, Wolf M, David V. Francis C, et al. Kidney Int. 2019 Dec;96(6):1346-1358. doi: 10.1016/j.kint.2019.07.026. Epub 2019 Aug 30. Kidney Int. 2019. PMID: 31668632 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous